Clinical trials: Complication of Dialysis
Renal Failure Acute Chronic
Efficacy and Tolerability of the APD Treatment in PAED Patients
The Silencia PD (peritoneal dialysis) cycler offers a pediatric (PAED) mode with advanced features such as Time and Volume Optimization (TAVO), supporting precise and individualized treatment.
- Trial name
- SilenciaPAED (NCT07004907)
- Testing
- Treatment with the pedriatic mode of the APD cycler
- Volunteers
- 13 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
- Trial name
- NCT03029208
- Testing
- Daprodustat, Darbepoetin alfa, Iron therapy
- Where
- 111 sites in United States, Argentina and 13 more
- Volunteers
- 312 people
- Sponsor
- GlaxoSmithKline
End Stage Kidney Disease
Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants
The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners
- Trial name
- NCT06613568
- Testing
- Moda-flx Hemodialysis System™
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Diality Inc.
Healthy, Renal Impairment
Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects
To investigate the Pharmacokinetics (PK) of oral administered Lacosamide in renal impaired subjects and healthy subjects.
- Trial name
- NCT01796938
- Testing
- Lacosamide tablet
- Where
- 2 sites in Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UCB BIOSCIENCES GmbH
Chronic Kidney Disease Stage 5
Quality of Life and Depression in Dialysis Patients
The aim of this study is to evaluate quality of life (QOL) and depression in peritoneal dialysis patients compare to hemodialysis patients and assess hydration effect on QOL and depression over time.
- Trial name
- QOLD (NCT01668628)
- Where
- South Korea
- Volunteers
- 1,068 people
- Sponsor
- Fresenius Medical Care Korea
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Daprodustat administration has the potential, by virtue of increasing hypoxia-inducible factor (HIF) levels, to increase oral iron absorption and incorporation into hemoglobin (Hgb).
- Trial name
- NCT03457701
- Testing
- Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease
A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients
PRT-201 is a protein that causes long lasting dilation of blood vessels when applied to the outside surface of the blood vessel.
- Trial name
- NCT00679991
- Testing
- PRT-201
- Where
- 11 sites in United States
- Volunteers
- 66 people
- Sponsor
- Proteon Therapeutics
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will allow exposure to MCI-196 for up to 52 weeks
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00542815
- Testing
- MCI-196, Another Phosphate binder (Sevelamer)
- Where
- 115 sites in Austria, Czechia and 13 more
- Volunteers
- 632 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease
A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease
PRT-201 is a recombinant human type-I pancreatic elastase intended for local, long-lasting dilation of the AVG venous anastomosis and outflow vein.
- Trial name
- PRT-201-102 (NCT01001351)
- Testing
- PRT-201
- Where
- 16 sites in United States
- Volunteers
- 89 people
- Sponsor
- Proteon Therapeutics
Chronic Kidney Disease
Dialysis Clinical Outcomes Revisited (DCOR) Trial
This is a randomized, open-label, parallel-design study to be conducted at 75 centers within the United States. The study will be described to hemodialysis patients.
- Trial name
- NCT00324571
- Testing
- Sevelamer hydrochloride, Calcium-based phosphate binder
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Hyperphosphatemia, End-stage Renal Disease
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
- Trial name
- NCT00648167
- Testing
- ferric citrate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Keryx Biopharmaceuticals
Anemia, Chronic Kidney Disease
Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis
The purpose of this study was to determine the dose ranges of peginesatide administered intravenously or subcutaneously that maintained hemoglobin in participants on dialysis whose hemoglobin values were stable on epoetin (alfa…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00434330
- Testing
- peginesatide
- Where
- 15 sites in Bulgaria, Romania and 1 more
- Volunteers
- 91 people
- Sponsor
- Affymax
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00037635
- Testing
- AMG 073
- Volunteers
- 400 people
- Sponsor
- Amgen
Congestive Heart Failure, Cardiac Transplantation
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor (nesiritide).
- Conditions
- Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
- Trial name
- NCT00338455
- Testing
- Natrecor (nesiritide)+Standard Care+dobutamine or milrinone
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Scios, Inc.
Chronic Kidney Disease, Not on Dialysis
Safety and Tolerability Study of MCI-196
The objective of this study is to assess the safety and tolerability of colestilan (MCI-196) in paediatric subjects (aged 2 years to <18 years) with CKD stages 3b to 5, diagnosed with hyperphosphataemia, who are not on dialysis.
- Conditions
- Chronic Kidney Disease, Not on Dialysis, Hyperphosphatemia, Paediatric
- Trial name
- NCT01818687
- Testing
- colestilan
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Renal Failure
A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure
A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic…
- Trial name
- NCT02681952
- Testing
- Renamezin capsule, Kremezin granule
- Where
- South Korea
- Volunteers
- 153 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
End Stage Renal Disease, ESRD
Safety and Efficacy Assessments of NeoKidney® in ESRD Patients Treated With Short Daily Hemodialysis
The goal of this clinical investigation is to asses the safety and efficacy a new sorbent-based hemodialysis device, NeoKidney® in ESRD patients treated with short daily hemodialysis.
- Trial name
- FIH Caen (NCT06024135)
- Testing
- NeoKidney
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Nextkidney S.A.
End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis
Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR
Phase IV post-marketing study to evaluate the effect of Extraneal on the HOMA index in non-diabetic CAPD patients over the long-dwell exchange.
- Trial name
- ECOS (NCT01093547)
- Testing
- Blood samples, Measure of peritoneal ultrafiltrates
- Where
- Colombia
- Sponsor
- Vantive Health LLC
Chronic Kidney Disease
Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis
This is a double-blind, randomized, active-control study with 2-study arms-darbepoetin alfa biosimilar and Aranesp, noninferiority trial design in dialysis patients.
- Trial name
- CKD (NCT05636891)
- Testing
- Stimus
- Where
- Vietnam
- Volunteers
- 43 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Kidney Failure, Chronic, Anemia
A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients
The purpose of this study in early hemodialysis patients (on dialysis 3 to 18 months) is to assess the effect of correction versus partial correction of anemia using epoetin alfa on heart pumping function.
- Trial name
- NCT00261521
- Testing
- epoetin alfa
- Volunteers
- 596 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.